当前位置: 首页 >> 检索结果
281. Fibrotic Plaque and Microvascular Dysfunction Predict Early Cardiac Allograft Vasculopathy Progression After Heart Transplantation: The Early Post Transplant Cardiac Allograft Vasculopathy Study.
作者: Sharon Chih.;Aun Yeong Chong.;Vladimír Džavík.;Derek Y So.;Natasha Aleksova.;George A Wells.;Jordan Bernick.;Christopher B Overgaard.;Ellamae Stadnick.;Lisa M Mielniczuk.;Rob S B Beanlands.;Heather J Ross.
来源: Circ Heart Fail. 2023年16卷6期e010173页
Early cardiac allograft vasculopathy (CAV) prognostication is needed to improve long-term outcomes after heart transplantation. We characterized first year posttransplant coronary anatomic-physiologic alterations to determine predictors of early CAV progression.
282. Economic Outcomes of Transcatheter Versus Surgical Aortic Valve Replacement in Patients with Severe Aortic Stenosis and Low Surgical Risk: Results from the PARTNER 3 Trial.
作者: Benjamin Z Galper.;Khaja M Chinnakondepalli.;Kaijun Wang.;Elizabeth A Magnuson.;Michael Lu.;Vinod H Thourani.;Susheel Kodali.;Raj Makkar.;Howard C Herrmann.;Samir Kapadia.;Mathew Williams.;John Webb.;Craig R Smith.;Michael J Mack.;Martin B Leon.;David J Cohen.; .
来源: Circulation. 2023年147卷21期1594-1605页
In patients with severe symptomatic aortic stenosis at low surgical risk, transfemoral transcatheter aortic valve replacement (TAVR) with the SAPIEN 3 valve has been shown to reduce the composite of death, stroke, or rehospitalization at 2-year follow-up compared with surgical aortic valve replacement (SAVR). Whether TAVR is cost-effective compared with SAVR for low-risk patients remains uncertain.
283. Rivaroxaban for Prevention of Thrombotic Events, Hospitalization, and Death in Outpatients With COVID-19: A Randomized Clinical Trial.
作者: Gregory Piazza.;Alex C Spyropoulos.;Judith Hsia.;Mark Goldin.;William J Towner.;Alan S Go.;Todd M Bull.;Stephen Weng.;Concetta Lipardi.;Elliot S Barnathan.;Marc P Bonaca.; .
来源: Circulation. 2023年147卷25期1891-1901页
COVID-19 (coronavirus disease 2019) is associated with heightened risks of venous and arterial thrombosis and hospitalization due to respiratory failure. To assess whether prophylactic anticoagulation can safely reduce the frequency of venous and arterial thrombosis, hospitalization, and death in nonhospitalized patients with symptomatic COVID-19 and at least one thrombosis risk factor, we conducted the PREVENT-HD double-blind, placebo-controlled randomized trial (A Study of Rivaroxaban to Reduce the Risk of Major Venous and Arterial Thrombotic Events, Hospitalization and Death in Medically Ill Outpatients With Acute, Symptomatic COVID-19] Infection).
284. Prognostic Importance of NT-proBNP (N-Terminal Pro-B-Type Natriuretic Peptide) Following High-Risk Myocardial Infarction in the PARADISE-MI Trial.
作者: Karola S Jering.;Brian L Claggett.;Marc A Pfeffer.;Christopher B Granger.;Lars Køber.;Eldrin F Lewis.;Aldo P Maggioni.;Douglas L Mann.;John J V McMurray.;Margaret F Prescott.;Jean L Rouleau.;Scott D Solomon.;Phillippe Gabriel Steg.;Dirk von Lewinski.;Eugene Braunwald.
来源: Circ Heart Fail. 2023年16卷5期e010259页
NT-proBNP (N-terminal pro-B-type natriuretic peptide) is a potent predictor of death and heart failure (HF) across multiple populations. We evaluated the prognostic importance of NT-proBNP in patients with acute myocardial infarction (MI) complicated by left ventricular systolic dysfunction, pulmonary congestion, or both and ≥1 of 8 risk-augmenting factors enrolled in the PARADISE-MI trial (Prospective ARNI vs ACE Inhibitor Trial to Determine Superiority in Reducing Heart Failure Events After Myocardial Infarction).
285. Empagliflozin Improves Left Atrial Strain in Patients With Type 2 Diabetes: Data From a Randomized, Placebo-Controlled Study.
作者: Kirsten Thiele.;Matthias Rau.;Julian Grebe.;Niels-Ulrik Korbinian Hartmann.;Ertunc Altiok.;Michael Böhm.;András P Keszei.;Nikolaus Marx.;Michael Lehrke.
来源: Circ Cardiovasc Imaging. 2023年16卷4期e015176页 286. Assessment of Cardiac Energy Metabolism, Function, and Physiology in Patients With Heart Failure Taking Empagliflozin: The Randomized, Controlled EMPA-VISION Trial.
作者: Moritz J Hundertmark.;Amanda Adler.;Charalambos Antoniades.;Ruth Coleman.;Julian L Griffin.;Rury R Holman.;Hanan Lamlum.;Jisoo Lee.;Daniel Massey.;Jack J J J Miller.;Joanne E Milton.;Shveta Monga.;Ferenc E Mózes.;Areesha Nazeer.;Betty Raman.;Oliver Rider.;Christopher T Rodgers.;Ladislav Valkovič.;Eleanor Wicks.;Masliza Mahmod.;Stefan Neubauer.
来源: Circulation. 2023年147卷22期1654-1669页
Sodium-glucose co-transporter 2 inhibitors (SGLT2i) have emerged as a paramount treatment for patients with heart failure (HF), irrespective of underlying reduced or preserved ejection fraction. However, a definite cardiac mechanism of action remains elusive. Derangements in myocardial energy metabolism are detectable in all HF phenotypes, and it was proposed that SGLT2i may improve energy production. The authors aimed to investigate whether treatment with empagliflozin leads to changes in myocardial energetics, serum metabolomics, and cardiorespiratory fitness.
287. Letter by Kambic et al Regarding Article, "A Randomized, Controlled Trial of Resistance Training Added to Caloric Restriction Plus Aerobic Exercise Training in Obese Heart Failure With Preserved Ejection Fraction".288. Effects of Atrial Fibrillation Screening According to N-Terminal Pro-B-Type Natriuretic Peptide: A Secondary Analysis of the Randomized LOOP Study.
作者: Lucas Yixi Xing.;Søren Zöga Diederichsen.;Søren Højberg.;Derk W Krieger.;Claus Graff.;Ruth Frikke-Schmidt.;Morten S Olesen.;Axel Brandes.;Lars Køber.;Ketil Jørgen Haugan.;Jesper Hastrup Svendsen.
来源: Circulation. 2023年147卷24期1788-1797页
Research suggests NT-proBNP (N-terminal pro-B-type natriuretic peptide) to be a strong predictor of incident atrial fibrillation (AF) and stroke. However, its utility in AF screening remains unknown. The aim of this study was to investigate NT-proBNP as a potential marker for screening efficacy with respect to AF yield and stroke prevention.
289. Association Between Hemoglobin Levels and Efficacy of Intravenous Ferric Carboxymaltose in Patients With Acute Heart Failure and Iron Deficiency: An AFFIRM-AHF Subgroup Analysis.
作者: Gerasimos Filippatos.;Piotr Ponikowski.;Dimitrios Farmakis.;Stefan D Anker.;Javed Butler.;Vincent Fabien.;Bridget-Anne Kirwan.;Iain C Macdougall.;Marco Metra.;Giuseppe Rosano.;Frank Ruschitzka.;Peter van der Meer.;Sandra Wächter.;Ewa A Jankowska.; .
来源: Circulation. 2023年147卷22期1640-1653页
Iron deficiency, with or without anemia, is an adverse prognostic factor in heart failure (HF). In AFFIRM-AHF (a randomized, double-blind placebo-controlled trial comparing the effect of intravenous ferric carboxymaltose on hospitalizations and mortality in iron-deficient subjects admitted for acute heart failure), intravenous ferric carboxymaltose (FCM), although having no significant effect on the primary end point, reduced the risk of HF hospitalization (hHF) and improved quality of life versus placebo in iron-deficient patients stabilized after an acute HF (AHF) episode. These prespecified AFFIRM-AHF subanalyses explored the association between hemoglobin levels and FCM treatment effects.
290. Angina After Percutaneous Coronary Intervention: Patient and Procedural Predictors.
作者: Damien Collison.;Samuel Copt.;Takuya Mizukami.;Carlos Collet.;Ruth McLaren.;Matthaios Didagelos.;Muhammad Aetesam-Ur-Rahman.;Peter McCartney.;Thomas J Ford.;Mitchell Lindsay.;Aadil Shaukat.;Paul Rocchiccioli.;Richard Brogan.;Stuart Watkins.;Margaret McEntegart.;Richard Good.;Keith Robertson.;Patrick O'Boyle.;Andrew Davie.;Adnan Khan.;Stuart Hood.;Hany Eteiba.;Colin Berry.;Keith G Oldroyd.
来源: Circ Cardiovasc Interv. 2023年16卷4期e012511页
Twenty percent to 40% of patients are affected by angina after percutaneous coronary intervention (PCI), which is associated with anxiety, depression, impaired physical function, and reduced quality of life. Understanding patient and procedural factors associated with post-PCI angina may inform alternative approaches to treatment.
291. Randomized Trial of Stand-Alone Use of the Antimicrobial Envelope in High-Risk Cardiac Device Patients.
作者: Christopher R Ellis.;Arnold J Greenspon.;John A Andriulli.;Paul A Gould.;Roger G Carillo.;Matthew J Kolek.;Rachel Donegan.;Ansel P Amaral.;Suneet Mittal.
来源: Circ Arrhythm Electrophysiol. 2023年16卷5期e011740页
Cardiac implantable electronic device (CIED) infection has a high mortality. Previous investigations showed reduced postoperative infections using skin preparation with chlorhexidine, preoperative intravenous antibiotics, and a TYRX-a antibacterial envelope. The additional benefit of antibiotic pocket wash and postoperative antibiotics has not been systematically studied.
292. Effectiveness of the Family Heart Talk Communication Tool in Improving Family Member Screening for Dilated Cardiomyopathy: Results of a Randomized Trial.
作者: Daniel D Kinnamon.;Elizabeth Jordan.;Garrie J Haas.;Mark Hofmeyer.;Evan Kransdorf.;Gregory A Ewald.;Alanna A Morris.;Anjali Owens.;Brian Lowes.;Douglas Stoller.;W H Wilson Tang.;Sonia Garg.;Barry H Trachtenberg.;Palak Shah.;Salpy V Pamboukian.;Nancy K Sweitzer.;Matthew T Wheeler.;Jane E Wilcox.;Stuart Katz.;Stephen Pan.;Javier Jimenez.;Keith D Aaronson.;Daniel P Fishbein.;Frank Smart.;Jessica Wang.;Stephen S Gottlieb.;Daniel P Judge.;Charles K Moore.;Jonathan O Mead.;Gordon S Huggins.;Hanyu Ni.;Wylie Burke.;Ray E Hershberger.; .
来源: Circulation. 2023年147卷17期1281-1290页
Managing disease risk among first-degree relatives of probands diagnosed with a heritable disease is central to precision medicine. A critical component is often clinical screening, which is particularly important for conditions like dilated cardiomyopathy (DCM) that remain asymptomatic until severe disease develops. Nonetheless, probands are frequently ill-equipped to disseminate genetic risk information that motivates at-risk relatives to complete recommended clinical screening. An easily implemented remedy for this key issue has been elusive.
293. Intracardiac Echocardiography-Guided Implantation for Proximal Left Bundle Branch Pacing.
作者: XiaoHui Kuang.;Xi Zhang.;YanJu Cui.;FeiYu Wei.;Peng Wu.;XiaoLong Gao.;Hong Xiang.;HaiYan Wu.;Li-Lin Wang.;Xiaohong Zhou.;Weijian Huang.;Jie Fan.
来源: Circ Arrhythm Electrophysiol. 2023年16卷4期e011408页
Multiple screw-in attempts under fluoroscopy are often needed to place the pacing lead tip near or at the left bundle branch (LBB). This study was conducted to evaluate the feasibility of implanting an LBB pacing lead in the proximal LBB (PLBB) guided by intracardiac echocardiography (ICE).
294. Comparison of 3- to 6-Month Versus 12-Month Dual Antiplatelet Therapy After Coronary Intervention Using the Contemporary Drug-Eluting Stents With Ultrathin Struts: The HOST-IDEA Randomized Clinical Trial.
作者: Jung-Kyu Han.;Doyeon Hwang.;Seokhun Yang.;Sang-Hyeon Park.;Jeehoon Kang.;Han-Mo Yang.;Kyung Woo Park.;Hyun-Jae Kang.;Bon-Kwon Koo.;Seung-Ho Hur.;Weon Kim.;Seok Yeon Kim.;Sang-Hyun Park.;Seung Hwan Han.;Sang-Hyun Kim.;Sanghoon Shin.;Yong Hoon Kim.;Kyungil Park.;Namho Lee.;Seung Jin Lee.;Jin Won Kim.;Hyo-Soo Kim.
来源: Circulation. 2023年147卷18期1358-1368页
Limited data are available on short-term dual antiplatelet therapy (DAPT) after percutaneous coronary intervention using third-generation drug-eluting stents with ultrathin struts and advanced polymer technology. We investigated whether 3- to 6-month DAPT was noninferior to 12-month DAPT after implantation of drug-eluting stents with ultrathin struts and advanced polymer technology.
295. Eliminating Medication Copayments for Low-Income Older Adults at High Cardiovascular Risk: A Randomized Controlled Trial.
作者: David J T Campbell.;Chad Mitchell.;Brenda R Hemmelgarn.;Marcello Tonelli.;Peter Faris.;Jianguo Zhang.;Ross T Tsuyuki.;Jane Fletcher.;Flora Au.;Scott Klarenbach.;Derek V Exner.;Braden J Manns.; .
来源: Circulation. 2023年147卷20期1505-1514页
One in eight people with heart disease has poor medication adherence that, in part, is related to copayment costs. This study tested whether eliminating copayments for high-value medications among low-income older adults at high cardiovascular risk would improve clinical outcomes.
296. Cluster Randomized Trial of a Personalized Clinical Decision Support Intervention to Improve Statin Prescribing in Patients With Atherosclerotic Cardiovascular Disease.
作者: Salim S Virani.;David J Ramsey.;Dax Westerman.;Mark K Kuebeler.;Liang Chen.;Julia M Akeroyd.;Glenn T Gobbel.;Christie M Ballantyne.;Laura A Petersen.;Alexander Turchin.;Michael E Matheny.
来源: Circulation. 2023年147卷18期1411-1413页 297. Effect of Electronic Nudges on Influenza Vaccination Rate in Older Adults With Cardiovascular Disease: Prespecified Analysis of the NUDGE-FLU Trial.
作者: Daniel Modin.;Niklas Dyrby Johansen.;Muthiah Vaduganathan.;Ankeet S Bhatt.;Simin Gharib Lee.;Brian L Claggett.;Erica L Dueger.;Sandrine I Samson.;Matthew M Loiacono.;Lars Køber.;Scott D Solomon.;Pradeesh Sivapalan.;Jens Ulrik Stæhr Jensen.;Cyril Jean-Marie Martel.;Palle Valentiner-Branth.;Tyra Grove Krause.;Tor Biering-Sørensen.
来源: Circulation. 2023年147卷18期1345-1354页
Influenza vaccines have been demonstrated to effectively reduce the incidence of influenza infection and potentially associated risks of cardiovascular events in patients with cardiovascular disease (CVD). Despite strong guideline and public health endorsements, global influenza vaccination rates in patients with CVD are highly variable. This prespecified analysis of NUDGE-FLU (Nationwide Utilization of Danish Government Electronic Letter System for Increasing Influenza Vaccine Uptake) examined the effect of digital behavioral nudges on influenza vaccine uptake based on the presence of CVD.
298. Self-Management Support Using Advertising Principles for Older Adults With Low Income at High Cardiovascular Risk: A Randomized Controlled Trial.
作者: David J T Campbell.;Marcello Tonelli.;Brenda R Hemmelgarn.;Peter Faris.;Jianguo Zhang.;Flora Au.;Ross T Tsuyuki.;Chad Mitchell.;Raj Pannu.;Tavis Campbell.;Noah Ivers.;Jane Fletcher.;Derek V Exner.;Braden J Manns.; .
来源: Circulation. 2023年147卷20期1492-1504页
Self-management education and support (SMES) interventions have modest effects on intermediate outcomes for those at risk of cardiovascular disease, but few studies have measured or demonstrated an effect on clinical end points. Advertising for commercial products is known to influence behavior, but advertising principles are not typically incorporated into SMES design.
299. On-Site Computed Tomography-Derived Fractional Flow Reserve to Guide Management of Patients With Stable Coronary Artery Disease: The TARGET Randomized Trial.
作者: Junjie Yang.;Dongkai Shan.;Xi Wang.;Xiaoqing Sun.;Meihua Shao.;Kan Wang.;Yueying Pan.;Zhiqiang Wang.;U Joseph Schoepf.;Rock H Savage.;Mei Zhang.;Mei Dong.;Lei Xu.;Yujie Zhou.;Xiang Ma.;Xinyang Hu.;Liming Xia.;Hesong Zeng.;Zinuan Liu.;Yundai Chen.
来源: Circulation. 2023年147卷18期1369-1381页
Computed tomography-derived fractional flow reserve (CT-FFR) using on-site machine learning enables identification of both the presence of coronary artery disease and vessel-specific ischemia. However, it is unclear whether on-site CT-FFR improves clinical or economic outcomes when compared with the standard of care in patients with stable coronary artery disease.
300. Prognostic Impact of Coronary Microvascular Dysfunction According to Different Patterns by Invasive Physiologic Indexes in Symptomatic Patients With Intermediate Coronary Stenosis.
作者: David Hong.;Doosup Shin.;Seung Hun Lee.;Hyun Sung Joh.;Ki Hong Choi.;Hyun Kuk Kim.;Sang Jin Ha.;Taek Kyu Park.;Jeong Hoon Yang.;Young Bin Song.;Joo-Yong Hahn.;Seung-Hyuk Choi.;Hyeon-Cheol Gwon.;Joo Myung Lee.
来源: Circ Cardiovasc Interv. 2023年16卷3期e012621页
Coronary microvascular dysfunction is a clinically significant component of ischemic heart disease. There can be heterogenous patterns of coronary microvascular dysfunction defined by invasive physiologic indexes such as coronary flow reserve (CFR) and index of microcirculatory resistance (IMR). We sought to compare the prognosis of coronary microvascular dysfunction according to different patterns of CFR and IMR.
|